Bizcommunity·2 min read·medium
Novo Nordisk v iDexis: What’s in a name (or, in this case, a compounded medicine)?
B
Bizcommunity
✦AI Summary
The Gauteng High Court has issued an interim order preventing a local pharmacy group from compounding weight-loss drugs containing semaglutide. Novo Nordisk sought the order to protect its branded products, Ozempic and Wegovy, while the pharmacy group disputes the safety and regulatory claims.
The Gauteng High Court ruled in favour of Novo Nordisk, issuing an interim order to prevent the local pharmacy group from manufacturing and selling weight-loss medicines containing semaglutide, the key ingredient in Novo Nordisk’s Ozempic and Wegovy.
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in